OpGenNASDAQ: OPGN

OpGen (NASDAQ: OPGN ) just reported results for the fourth quarter of 2023. OpGen reported earnings per share of -$17.67.

ROCKVILLE, Md., May 24, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the “Form 10-Q”), which serves as an additional basis for delisting the Company's securities from Nasdaq, and that the Nasdaq Hearings Panel will consider this matter in connection with the continued listing of the Company's securities on Nasdaq. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (the “SEC”).

OpGen, Inc. (Nasdaq: OPGN) announced today that its board of directors has approved a 1-for-10 reverse stock split of its common stock, which will be effective at 12:01 a.m. EST on May 20, 2024. The Company's common stock will begin trading on The Nasdaq Capital Market under the symbol "OPGN" on a post-split basis. The new CUSIP number for the Company's common stock after the Reverse Stock Split will be 68373L505.

OpGen (NASDAQ: OPGN ) stock is on the rise Friday after the precision medicine company withdrew a share offering. A filing with the Securities and Exchange Commission (SEC) has the company requesting the withdrawal of its Registration Statement on Form S-1.